T cell immune awakening in response to immunotherapy is age-dependent.
Age
Immune-checkpoint blockade
Immunotherapy
Melanoma
T cell
T cell receptor
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
10
08
2021
revised:
29
10
2021
accepted:
08
11
2021
pubmed:
25
12
2021
medline:
22
4
2022
entrez:
24
12
2021
Statut:
ppublish
Résumé
Precision immuno-oncology approaches are needed to improve cancer care. We recently demonstrated that in patients with metastatic melanoma, an increase of clonality or diversity of the T cell receptor (TCR) repertoire of peripheral T cells following one cycle of immunotherapy is coincident with response to immune-checkpoint blockade (ICB). We also identified a subset of peripheral CD8 Fifty patients with metastatic melanoma treated with first-line anti-PD-1 ICB were included. We analysed TCR repertoire and peripheral T We observed a correlation between T We demonstrate that immunotherapy-induced immune-awakening patterns in patients with melanoma are age-related and may impact patient response to ICB, and thus have implications for biomarker development and planning of personalised therapeutic strategies.
Sections du résumé
BACKGROUND
Precision immuno-oncology approaches are needed to improve cancer care. We recently demonstrated that in patients with metastatic melanoma, an increase of clonality or diversity of the T cell receptor (TCR) repertoire of peripheral T cells following one cycle of immunotherapy is coincident with response to immune-checkpoint blockade (ICB). We also identified a subset of peripheral CD8
METHODS
Fifty patients with metastatic melanoma treated with first-line anti-PD-1 ICB were included. We analysed TCR repertoire and peripheral T
RESULTS
We observed a correlation between T
CONCLUSIONS
We demonstrate that immunotherapy-induced immune-awakening patterns in patients with melanoma are age-related and may impact patient response to ICB, and thus have implications for biomarker development and planning of personalised therapeutic strategies.
Identifiants
pubmed: 34952479
pii: S0959-8049(21)01225-9
doi: 10.1016/j.ejca.2021.11.015
pmc: PMC8829752
pii:
doi:
Substances chimiques
Immunologic Factors
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-21Subventions
Organisme : Cancer Research UK
ID : A22902
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A27412
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100282/Z/12/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement RM is an expert witness for Pfizer. RM may benefit from drug discovery programmes that are commercialized. PL serves as a paid advisor/speaker for Bristol-Myers Squibb, Merck Sharp and Dohme, Roche, Novartis, Amgen, Pierre Fabre, Nektar, Melagenix. PL reports travel support from Bristol-Myers Squibb and Merck Sharp and Dohme, and receives research support from Bristol-Myers Squibb. AG received honoraria and consultancy fees from BMS and Novartis. All remaining authors have declared no conflicts of interest.
Références
J Hematol Oncol. 2019 Dec 18;12(1):139
pubmed: 31852498
Exp Gerontol. 2013 Dec;48(12):1436-42
pubmed: 24120567
J Immunol. 2014 Mar 15;192(6):2689-98
pubmed: 24510963
Clin Cancer Res. 2018 Nov 1;24(21):5347-5356
pubmed: 29898988
Cancer J. 2017 Jul/Aug;23(4):201-205
pubmed: 28731941
Nat Cancer. 2020 Feb;1(2):210-221
pubmed: 32110781
Pigment Cell Melanoma Res. 2018 Jan;31(1):73-81
pubmed: 28786531
Nat Commun. 2021 Jul 2;12(1):4098
pubmed: 34215730
Clin Exp Immunol. 2017 Jan;187(1):53-63
pubmed: 27690272
Oncologist. 2020 Feb;25(2):e381-e385
pubmed: 32043765
Exp Gerontol. 2014 Jun;54:71-4
pubmed: 24440389
J Clin Endocrinol Metab. 2018 Feb 1;103(2):689-697
pubmed: 29220531
J Hematol Oncol. 2020 Nov 10;13(1):151
pubmed: 33168037
Clin Exp Immunol. 2010 Sep;161(3):497-503
pubmed: 20646007
Eur J Cancer. 2017 Sep;82:155-166
pubmed: 28689093
Clin Pract (Lond). 2014;11(6):749-762
pubmed: 25642321
An Acad Bras Cienc. 2017 Jan-Mar;89(1):285-299
pubmed: 28423084
Front Immunol. 2013 Oct 07;4:316
pubmed: 24109481
Nat Med. 2019 Feb;25(2):221-224
pubmed: 30510256
Nat Rev Immunol. 2004 Feb;4(2):123-32
pubmed: 15040585
Pigment Cell Melanoma Res. 2011 Apr;24(2):345-51
pubmed: 21324100